Loading clinical trials...

Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease | Clinical Trials | Clareo Health

RECRUITINGNA

Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease

NCT06359795•Peking University Third Hospital

View on ClinicalTrials.gov

Summary

FAPI PET has been developed as a promising approach for the evaluation of fibroinflammatory, such as in inflammatory bowel disease. This prospective study aims to explore the value of 18F-AlF-FAPI PET/CT in assessing the activity of Thyroid Eye Disease (TED) and investigate whether FAPI PET/CT may be superior to 99mTc-DTPA SPECT/CT for the diagnosis, therapy response assessment, and follow-up of TED.

Detailed Description

Subjects with TED underwent 18F-AlF-FAPI PET/CT and 99mTc-DTPA SPECT/CT for activity assessment within a 10-day period. On 18F-AlF-FAPI PET/CT, uptake in the extraocular muscles was quantified using SUV metrics and target-to-background ratio. On 99mTc-DTPA SPECT/CT, uptake in the extraocular muscles was semi-quantified using the uptake ratio. Activity of TED was determined through comprehensive clinical data. The correlation between SUV metrics and activity status was calculated to explore the value of 18F-AlF-FAPI PET/CT in assessing TED activity. The diagnostic accuracy of 18F-AlF-FAPI PET/CT and 99mTc-DTPA SPECT/CT in assessing TED activity was compared. Additionally, the correlation of changes in SUV metrics and therapy response will be calculated to explore the value of 18F-AlF-FAPI PET/CT in therapy response assessment of TED.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Age ≥ 18 years;
•2. Patients diagnosed with TED;
•3. Complete understanding and voluntary participation in this study, with the signing of an informed consent form.

Exclusion Criteria

•1. Severe liver or kidney dysfunction;
•2. Inability to maintain a supine position for 5 minutes to cooperate with the examination;
•3. Suffering from claustrophobia or other psychiatric disorders;
•4. Patients planning pregnancy or in the prenatal or lactation period;
•5. Other conditions deemed unsuitable for participation in the trial by the investigator.

Locations (1)

Dept. of Nuclear Medicine, Peking University Third Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

December 15, 2023

Primary Completion Date

December 31, 2027

Completion Date

December 31, 2027

Last Updated

April 11, 2024

Enrollment

ESTIMATED participants

Conditions

Thyroid Eye Disease

Interventions

18F-AlF-FAPI PET/CT, 99mTc-DTPA SPECT/CT

DIAGNOSTIC_TEST

Contacts

Hui Li, Dr.

CONTACT

86-13121136769 huilee1990@163.com

Lingge Suo, Dr.

CONTACT

86-010-82264935 suolingge_1019@126.com

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

NCT06112340

Thyroid Eye DiseaseGraves Orbitopathy+10 more

View study

RECRUITING

Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting

NCT05012033

Thyroid Eye DiseaseVasculitis+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 11, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease

Inclusion Criteria

Exclusion Criteria

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting

A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease

A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301